Introduction
Cost-utility analysis is practiced by many healthcare authorities, such as the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) in the UK and the Tandvårds-& läkemedelsförmånsverket (TLV) in Sweden, and is one of the most commonly used forms of economic evaluation [1, 2] . This approach takes into account the cost, the quality and the length of life, which are combined as a cost per quality-adjusted life year. For this, quality of life is measured by a utility value -health states are located on this scale based on individuals' preferences, which are elicited by techniques such as time trade off, visual analogue scale or standard gamble.
Although many instruments can be used to measure quality of life, it is not always possible to generate utilities from the results [2] . Generic preference-based instruments, such as the EQ-5D-3L, are typically used to measure quality of life in disease [3] . For many of these instruments, the responses can be transformed into utilities using available population tariffs based on these preferences. The use of condition-specific instruments in clinical trials is also widespread to gain insight on how an intervention affects particular symptoms of a disease.
Such instruments are believed to be more sensitive to changes in disease symptoms, and they may allow label claims by the US Food and Drug Administration regarding patient-reported outcomes. However, population preferences are generally not available for these metrics, and those that are available seldom have the level of research that has been performed on generic instruments [2] . Owing to the lack of population preference data, it is typically not possible to generate utilities -a solution for this is to map onto generic measures, such as the EQ-5D-3L, by establishing a relationship between the two instruments using regression techniques [3] .
The EORTC-QLQ-C30 is one such condition-specific measure, being specific to cancer. As well as more general symptoms, such pain, it also covers symptoms that are more typically associated with cancers such as fatigue, gastrointestinal symptoms and financial concerns.
Using the Oxford mapping database [4] , we identified nine mappings between the EORTC-QLQ-C30 and the EQ-5D-3L performed across a range of cancers. Of these, five used EQ-5D-3L with the UK tariff. Similarly Doble et al. [5] performed a systematic review, identifying the same nine studies, and one additional study, and applied them to a large Australian dataset (3560 observations) to assess predictive accuracy and external validity across a range of cancers. Two of the 10 studies in the work by Doble et al. [5] showed particularly good external validity: those by Longworth et al. [3] (which used the UK EQ-5D-3L tariff) and Versteegh et al. [6] (which used the Dutch EQ-5D-3L tariff). In addition to the mappings to the EQ-5D-3L, a set of population preferences of 674 of multiple myeloma patients, the EORTC-8D, has been developed by Rowen et al. [7] . However, none of the published studies that used the UK tariff were conducted in, or included, patients with mCRC. The lack of existing mapping algorithms in this patient population means that mappings from alternative cancers must be used to derive utility values from EORTC-QLQ-C30 in mCRC. This may lead to a potential bias of unknown magnitude and direction, as it is possible that the symptoms of different cancers may have different affects. Therefore, the objectives of this study were to perform a mapping of the EORTC-QLQ-C30 scores to EQ-5D-3L in patients with liver-only or liver-dominant mCRC and to compare the predictive validity of existing methods of utility generation from the EORTC-QLQ-C30 score in this patient population.
Methods

Instruments
The EQ-5D-3L is a generic quality of life instrument that is widely used in economic evaluation [1] . The instrument consists of five items (mobility, self-care, usual activities, pain and anxiety and depression), each of which has three levels; this results in 243 possible health states in which a patient can reside.
The EORTC-QLQ-C30 is a cancer-specific quality of life instrument. It consists of 30 items from which five function scores, nine symptom scores and a global score can be derived based on the individual responses [8] . These instruments are standardised questionnaires with translations that are tested for linguistic and content validity.
Data and software
SIRFLOX was a randomised, multicentre trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard chemotherapy in patients with previously untreated mCRC [9] . Chemotherapy-naïve patients with liver metastases with or without limited extra-hepatic metastases were In the trial, EQ-5D-3L was completed at baseline, 3 months, 6 months, 12 months and then yearly. EORTC-QLQ-C30 was collected at baseline, 1 month and 12 months. There was also a small proportion of patients that completed the EORTC-QLQ-C30 at 3 months. Patients were recruited from 87 centres in Australia, Europe, Israel, New Zealand and the United States [9] .
All analyses were performed in the statistical software R (version 3.2.2), using the packages MASS, nlme and VGAM.
Mapping analyses
The methods published in the MAPs statement [10] and the work by Longworth et al. [3] were followed to guide selecting the appropriate model and conducting the analyses.
A linear mixed regression was used to model EQ-5D-3L utility values as a function of the five function scores, nine symptom scores and the global score from the EORTC-QLQ-C30 questionnaire. A linear mixed regression model consists of both fixed effects and random effects and was used to allow for multiple observations per individual, which are likely to be correlated.
A Tobit regression was also performed. This model, also known as a censored regression model, estimates linear relationships between variables where there is either left or right censoring [11] . Values that are at or above a threshold take on the value of that threshold.
This model was explored as it takes into account that the EQ-5D-3L utility values cannot be greater than one and is also an approach that has been used in previous mapping algorithms [3, 12, 13] . As with the linear mixed regression, EQ-5D-3L utility values were modelled as a function of the 15 scores available from the EORTC-QLQ-C30 questionnaire.
For use in the regression analysis, observations measured from the same patient within the same visit were paired. Measurements without a corresponding data point in the alternative instrument were dropped from the analysis -as a result, no observations were used from the EQ-5D-3L questionnaires collected at 6 months or post 12 months, and only a fraction of those collected at 3 months were used. The EORTC-QLQ-C30 observations collected at 1 month were dropped from the analysis for the same reason.
The minimum difference considered to be clinically important for this analysis was 0.08 [14] .
For validation of previously published algorithms, we used the sample of matching observations to calculate the mean of the EQ-5D-3L utility values at baseline, pre-progression and post-progression using all eligible mapping algorithms. Where more than one algorithm was available, the author's preferred algorithm was used. Only studies where the UK EQ-5D-3L tariff had been used were included (five studies) to allow a comparison of results. EORTC-8D values were also derived from the EORTC-QLQ-C30, using the mapping algorithm reported by Rowen et al. [7] .
Performance of mapping algorithms
We used statistical measures to assess the goodness of fit of the models including the mean absolute error (MAE), root mean squared error (RMSE) and adjusted R 2 . These performance measures are used to assess goodness of fit in the majority of mapping studies and so using these allows for an easy comparison to existing models. We also plotted the fitted values against the observed values as quantile-quantile plots to visually assess fit, as well as testing the fit of the model in each quartile of results.
Results
Our analysis included 529 patients who completed a total of 1740 EQ-5D-3L observations (1100 pre-progression, 108 post-progression and 456 where progression status is unreported) and 1241 EORTC-QLQ-C30 observations (789 pre-progression, 108 post-progression and 344 where progression status is unreported) [9] . This is shown in Table 1 .
[ Table 1 here] The intraclass correlation coefficient as a measure of the correlation within patients of the utility score was 0.386.
Following the matching of observations, 707 pairs of observations were included in the analysis. Of these, 455 were pre-progression, 64 were post-progression and 188 observations had an unreported progression status. The patient demographics of this sample are described in Table 2 . The mean EQ-5D-3L utility from these paired observations was, on the control arm, 0.80 at baseline, 0.81 pre-progression and 0.72 post-progression and, on the SIRT arm, 0.78 at baseline, 0.78 pre-progression and 0.84 post-progression (Table 3) . [ Table 2 and Table 3 here]
The regression results for the linear mixed regression model are shown in Table 4 . Four of the five function scores were positive and statistically significant (p<0.01), with social functioning being the only exception. The global score was also positive and statistically significant (p<0.05). As would be expected, the pain symptom score had a negative impact on EQ-5D-3L utility (p<0.00001), as did financial problems (p<0.01). The algorithm is a simple additive model. To get the utility value it can be applied to a data set by multiplying all the coefficients (reported in Table 4 ) by the corresponding EORTC-QLQ-C30 scores and adding the sum of these to the constant. [ Table 4 here]
The results for the Tobit model were similar to those from the linear mixed regression model (Table 4) ; the global score and all function scores, except for social functioning, were positive and associated with improved quality of life (p<0.01). Coefficients for pain (p<0.00001), financial problems (p<0.005) and appetite loss (p<0.05) also reached statistical significance in this model.
Predictive performance
The MAE for the linear mixed regression model was 0.127 and the RMSE was 0.092. These showing the regression to be a relatively good predictor of EQ-5D-3L utility based on EORTC-QLQ-C30 score (but again, worse than the linear mixed regression model). The residuals from the linear mixed regression model ranged from -0.6 to 0.4, with the majority at 0. This was much smaller than the Tobit model where residuals ranged from -2 to 6. Data were ordered by utility values, from highest to lowest, and divided into quartiles. Table 5 shows the fit to the data for each quartile. The results show that both models slightly underestimate utility in the less severe states and slightly overestimate utility in the more severe states. This is to be expected considering the nature of the EQ-5D measure. The model shows a good fit to the middle 50% of the data. [ Table 5 here] The fit was also tested for when the observed utility is equal to 1 and <0. Table 6 lists the relevant papers identified in Oxford database [4] , and in the paper by Doble et al. [5] , and shows the results for the analyses that we conducted using the five published algorithms between the EORTC-QLQ-C30 and EQ-5D-3L, which were scored using the UK value set. Mapping analyses were not performed for all studies identified, only those using the UK tariff. The estimated mean utility for three of the five published mappings closely matched the observed EQ-5D-3L utility (mean utility within 10%) [3, 15, 16] , while for two of the mappings the mean utility did not match well [17, 18] . Of those that did not fit well, Of the algorithms that did match the data well (despite being from different disease areas), two underestimated [3, 16] , and one over-estimated [15] , the EQ-5D-3L utility. The two that underestimated EQ-5D-3L were used for patients with multiple myeloma. The study by Kontodimopoulos et al. was used for patients with gastric cancer, a disease with symptoms similar to those seen in mCRC. [ Table 6 here]
Comparison to other mapping studies and EORTC-8D
The utilities derived from the EORTC-8D are shown in Table 7 and show a similar pattern to the EQ-5D-3L values from the SIRFLOX study for all arms (see Table 3 ), although most values are approximately 0.05 higher than the equivalent EQ-5D-3L utility value. [ Table 7 here]
Discussion
The aim of this study was to map EORTC-QLQ-C30 values to EQ-5D-3L in patients with liver-only or liver-dominant mCRC, based on data collected in the SIRFLOX clinical trial.
Both the mixed effects and Tobit models showed a good fit to the data. Owing to the nature of the Tobit model, where censoring limited the utility values to fall within the bound of the EQ5D-3L (-0.59 to 1.00), it would be expected that the Tobit model has the better fit to the data. The results showed that the Tobit model provides a reasonable fit to the data, as demonstrated by a low RMSE and MAE and a high adjusted R 2 . However, the linear mixed regression model performed better in all measures of goodness of fit, and thus it is our preferred model.
When comparing results obtained with the SIRFLOX data using algorithms from other mapping studies, three studies performed well and two provided poor estimates of observed utility. The reasons for these discrepancies are unclear, but they may be related to the disease areas used, the severity of patients varying between studies or simply chance. The review paper by Doble et al. [5] recommended the Longworth et al. algorithm [3] as providing a good fit to external data, and it also showed a good fit to our data (it predicted a utility of 0.75 compared to an observed utility of 0.79). The other algorithm recommended by Doble et al.
[5] (Versteegh et al. [6] ) was not included in our analysis as it was not based on the UK EQ-5D-3L tariff.
Although we only have data from a single stage of disease, we did find support for the three algorithms that fit our data. The mapping that provided the closest fit to the observed data (Kontodimopoulos et al. -0.80 versus 0.79) was conducted in gastric cancer [15] , which we would expect to have symptoms more similar to liver-only or liver-dominant mCRC than other conditions used in the mappings. It should be researched further whether this was by chance or due to a systemic relationship between the instruments based on disease area.
Our results are consistent with those that have been previously reported, where mapping from different mappings from EORTC-QLQ-C30 to EQ5D-3L can result in varied predicted utilities [19] . Additionally, our studies further show that mapping EORTC-QLQ-C30 to EQ5D-3L tends to overestimate EQ-5D-3L utility values in the more severe health states [19] . Further research is required into alternative regression methods, which more accurately predict EQ-5D-3L utility from EORTC-QLQ-C30, particularly towards the edges of the distribution.
The main limitation of the study was the lack of meaningful observations post-progression (67 paired observations). For this reason, we are unable to test whether the mapping holds at the next (or previous) stage of the disease. Although we would not expect the relationship between the instruments to change, due to the lack of protocol-driven visits at the same time points, we are not able to confirm this is the case. A second limitation is that the study was conducted using the EQ-5D-3L rather than the EQ5D-5L, which is now available and contains five levels per item rather than three. It is expected that this version is more sensitive to changes in quality of life and may soon be replace the three level version. A further limitation is that patients in the study were drawn from numerous countries and spoke multiple languages, and it is possible that this may have impacted on the results.
In conclusion, this study is the first of its kind in liver-only or liver-dominant mCRC and in mCRC as a condition. The mapping constructed shows a good fit to the data and provides practitioners with an additional mapping between EORTC-QLQ-C30 and EQ-5D-3L using a large dataset in a previously unstudied disease area. Further research into the link between EORTC-QLQ-C30 and EQ-5D-3L in different datasets is needed. This should include a range of cancers, both in type and severity, to further assess the predictive accuracy of mappings and whether a generic mapping function is likely to be valid, irrespective of the site of disease, or whether different mappings are needed for different cancers. 
